January 5, 2022 10:53 AM EST
News Briefing

An­nex­on shares fall 33% af­ter pa­tients drop out of Hunt­ing­ton's tri­al; Two Chi­nese biotechs net mod­est fi­nanc­ing rounds

Paul Schloesser

Associate Editor

An­nex­on has some dis­ap­point­ing news, and it is ev­i­dent at the Nas­daq.

An­nex­on, which went pub­lic back in 2020, had its share price $AN­NX …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times